Colitis Ulcerosa Bibliografía 1. Wilks S. Morbid appearances in the intestines of Miss Bankes. Med Times Gazette 1859;2:264-5. 2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA 1932;99:1323-9. 3. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a populationbased inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40. 4. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006;5:197-209. 5. Xavier RJ, Podolsky D. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. 6. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78. 7. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97. [Erratum, Gastroenterology 2009;136:1844.] 8. Shanahan F. Pathogenesis of ulcerative colitis. Lancet 1993;342:407-11. 9. Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2004;1:26-31. 10. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17. 11. Kugathasan S, Cohen S. Searching for new clues in inflammatory bowel disease: tell tales from pediatric IBD natural history studies. Gastroenterology 2008;135:1038-41. 12. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010;11:134-47. 13. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394-400. 14. Birrenbach T, B.cker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004;10:848-59. 15. Rutgeerts P, D’Haens G, Hiele M, Geboes K, VanTrappen G. Appendectomy protects against ulcerative colitis. Gastroenterology 1994;106:1251-3. 16. Hugot J-P, Chamaiilard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599-603. 17. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:603-6. 18. Duerr RH. Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. Gastroenterology 2007;132:2045-9. 19. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:24652. 20. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011;17:831-48. 21. Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-9. 22. MacDonald TT. Breakdown of tolerante to the intestinal bacterial flora in inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:445-7. 23. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature 2007;449:804-10. 24. Sartor RB. Microbial influences in inflammatory bowel disease. Gastroenterology 2008;134:577-94. 25. Prantera C. What role do antibiotics have in the treatment of IBD? Nat Clin Pract Gastroenterol Hepatol 2008;5:670-1. 26. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO. pANCA represents a crossreactivity to enteric bacterial antigens. J Clin Immunol 1998;18:153-60.

27. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-44. [Erratum, Nat Rev Immunol 2010;10:215.] 28. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expresión of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7. 29. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-11. 30. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 2007;39:830-2. 31. Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissuebound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 1985;76:311-8. 32. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67. 33. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7. 34. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64. 35. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70. 36. Kaser A, Zeissing S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621. 37. Gibson P, Rosella O, Nov R, Young G. Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal cancer. Gut 1995;36:857-63. 38. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferatoractivated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265-76. 39. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60. 40. Kaser A, Lee A-H, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008;134:743-56. 41. Bhagat S, Das KM. A shared and unique epitope in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994;107:103-8. 42. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoform in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998;114:912-22. 43. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23. 44. Dendrinos K, Cerda S, Farraye FA. The “cecal patch” in patients with ulcerative colitis. Gastrointest Endosc 2008;68:1006-7. 45. D’Haens G, Sandborn WJ, Feagan B, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86. 46. Bergeron V, Vienne A, Sokol H, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010;105:2405-11. 47. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a populationbased cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-95. 48. Rex DK. Preventing colorectal cancer and cancer mortality with colonoscopy: what we know and what we don’t know. Endoscopy 2010;42:320-3. 49. Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol 2006;126:365-76. 50. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;2:CD000279. 51. Rodriguez SA, Collins JM, Knigge KL, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc 2007;65:432-9.

52. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-8. 1 53. van den Broek FJ, Fockens P, van Eeden S, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008;57:1083-9. 54. Loddenkemper C. Diagnostic standards in the pathology of inflammatory bowel disease. Dig Dis 2009;27:576-83. 55. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-89. 56. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91. 57. Linskens RK, Mallant-Hent RC, Groothuismink ZM, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn’s disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 2002;14:1013-8. 58. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62. 59. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23. [Erratum, Am J Gastroenterol 2010;105:500.] 60. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:160-70. 61. Lucidarme D, Marteau P, Foucault M, Vautrin B, Filoche B. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Aliment Pharmacol Ther 1997;11:335-40. 62. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;1:CD004115. 63. Gionchetti P, D’Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol 2005;39:291-7. 64. Connolly MP, Poole CD, Currie CJ, Marteau P, Nielsen SK. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009;80:241-6. 65. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85. 66. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-9. 67. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of onceor twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902. 68. J.rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. 69. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS Trial. J Crohns Colitis 2011;5:Suppl:s68. abstract. 70. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84. 71. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. [Erratum, N Engl J Med 2006;354:2200.] 72. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.

73. Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011;60:3-9. 74. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000544. 75. D’Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7. 76. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;1:CD000478. 77. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53. 78. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25. 79. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54. 80. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1971 is as effective as with Standard mesalazine. Gut 2004;53:1617-23. 81. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a doubleblind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-27. 82. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15. 83. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 2008;40:821-6. 84. Cannom RR, Kaiser AM, Ault GT, Beart RW Jr, Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg 2009;75:976-80. 85. Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005;48:1997-2009. 86. Wikland M, Jansson I, Asztély M, et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Colorectal Dis 1990;5:49-52. 87. Camilleri-Brennan J, Munro J, Steele RJ. Does an ileoanal pouch offer a better quality of life than a permanent ileostomy for patients with ulcerative colitis? J Gastrointest Surg 2003;7:8149. 88. Leowardi C, Hinz U, Tariverdian M, et al. Long-term outcome 10 years or more after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Langenbecks Arch Surg 2010;395:49-56. 89. Wu H, Shen B. Pouchitis and pouch dysfunction. Gastroenterol Clin North Am 2009;38:65168. 90. Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009;15:1424-31. 91. Bronner MP, O’Sullivan JN, Rabinovitch PS, et al. Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am J Pathol 2008;173:1853-60. 92. Lichtenstein GR, Rutgeerts P. Importante of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46. 93. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212. 94. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7. 95. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005;352:2499-507.

96. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75. 97. Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55. 98. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007;13:1365-8.